ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1722

Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire

Laurette van Boheemen1, Marieke ter Wee2, Marie Falahee3, Marian van Beers4, Axel Finckh5, Aase Hensvold6, Karim Raza7 and Dirkjan van Schaardenburg8, 1Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, 2Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, 3Sandwell and West Birmingham Hospitals NHS Trust, Birminham, United Kingdom, 4Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, 5Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, 6Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 7Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, 8Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands

Meeting: ACR Convergence 2020

Keywords: rheumatoid arthritis, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Accurate prediction of rheumatoid arthritis (RA) development in persons at risk can help to select individuals for early intervention trials. At-risk individuals exhibit a high prevalence of diverse symptoms 1,2 and information on the predictive ability of symptoms or symptom complexes is still largely lacking. We investigated if symptoms could predict RA development in persons at risk, using the validated ‘Symptoms in Persons At Risk of Rheumatoid Arthritis’ (SPARRA) questionnaire.

Methods: Individuals at-risk of RA from four different cohorts from the Netherlands (n=122), United Kingdom (n=77), Sweden (n=13) and Switzerland (n=20), were asked to complete the SPARRA questionnaire, consisting of 69 questions (previously described 3). Individuals were persons with anticitrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF; n=135), having relevant symptoms (arthralgia suspicious for progression to RA) with or without RA-specific antibodies, (n=77) or first degree relatives (FDR, n=20) of RA patients. Follow up was ≥ 24 months or until clinical arthritis development. Univariable analyses preselecting possible predictors (Cox regression, p< 0.2) was followed by stepwise forward selection (p< 0.1) to create a multivariable prediction model. To test the added value of the SPARRA items over the clinical prediction model by van de Stadt et al 4, the likelihood ratio (LR) test was used to compare the van de Stadt model with and without SPARRA items

Results: The mean age of all participants was 51 years, 69% was female. In total, 58 persons (25%) developed clinical arthritis (n=23, 26, 7, 2 respectively in the 4 groups) after a median of 7 months (IQR 5.3 – 17.8). In total, 22 SPARRA questions were preselected and entered in the stepwise forward selection procedure. The symptoms that predicted time to development of arthritis are shown in table 1. The symptom ‘pain that moves from one side to the other’ showed added value to the van de Stadt model in predicting arthritis (LR test p = 0.012, AUC 0.73 (extended model) versus AUC 0.71 (van de Stadt model)).

Conclusion: Specific symptom details such as pattern of pain or degree of joint swelling can provide useful additional information to estimate a person’s RA risk. Our next steps are 1) to develop a new prediction model using both SPARRA data and clinical data and distinguishing between seropositive and seronegative individuals and 2) to create a shortened version of the SPARRA questionnaire to be used in prospective at-risk cohorts to enable homogenous symptom data collection. This will further improve our understanding of the prevalence and predictive ability of greatly diverse symptoms in different at-risk populations.

  1. Smolik I et al. J Rheumatol. 2013;40(6):818-24.
  2. Stack RJ et al. Arthritis Care Res (Hoboken). 2013;65(12):1916-26.
  3. van Beers-Tas MH et al. RMD Open. 2018;4(1):e000641.
  4. van de Stadt LA et al. Ann Rheum Dis. 2013;72(12):1920-6.

Table 1 Multivariable prediction model of SPARRA questions to predict clinical arthritis


Disclosure: L. van Boheemen, None; M. ter Wee, None; M. Falahee, None; M. van Beers, None; A. Finckh, Pfizer, 2, 8, Bristol-Myers Squibb Company, 2, 8, Eli Lilly, 2, 8, AbbVie, 8, AB2Bio, 8, Sandoz, 8, Sanofi, 8; A. Hensvold, None; K. Raza, Pfizer, 2; D. van Schaardenburg, None.

To cite this abstract in AMA style:

van Boheemen L, ter Wee M, Falahee M, van Beers M, Finckh A, Hensvold A, Raza K, van Schaardenburg D. Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/predicting-rheumatoid-arthritis-using-the-symptoms-in-persons-at-risk-of-rheumatoid-arthritis-sparra-questionnaire/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-rheumatoid-arthritis-using-the-symptoms-in-persons-at-risk-of-rheumatoid-arthritis-sparra-questionnaire/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology